Auris Medical Holding (EARS) Reports Complete Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
Tweet Send to a Friend
Top-line results from the HEALOS trial are expected in the fall of 2017Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE